Netupitant and Palonosetron

DRUG3 trials

Sponsors

Helsinn Healthcare SA, Joseph Ma

Conditions

Chemotherapy Induced Nausea VomitingChemotherapy-Induced Nausea and Vomiting

Phase 2

Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV

TerminatedNCT03008213

Joseph MaChemotherapy Induced Nausea Vomiting

Start: 2017-01-31End: 2018-01-22Updated: 2019-12-09

Phase 3

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

CompletedNCT01339260

Helsinn Healthcare SAChemotherapy-Induced Nausea and Vomiting

Start: 2011-04-30Updated: 2014-11-26

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

CompletedNCT01376297

Helsinn Healthcare SAChemotherapy-Induced Nausea and Vomiting

Start: 2011-07-31Updated: 2014-11-17

Related Papers

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

Cancer Medicine2019-04-0917 citations

Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.

2017-03-107 citations

Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.

2016-06-2218 citations

Should all antiemetic guidelines recommend adding a NK<sub>1</sub> receptor antagonist (NK<sub>1</sub>RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK<sub>1</sub>RA, netupitant, and palonosetron.

Journal of Clinical Oncology2015-05-205 citations

Evaluation of nausea control with NEPA, a novel oral combination antiemetic.

Journal of Clinical Oncology2014-11-015 citations

Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.

Journal of Clinical Oncology2014-05-2012 citations

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

2014-03-14131 citations

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

2014-03-05180 citations

Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).

Journal of Clinical Oncology2013-06-202 citations